Recent Advances in Autoimmune Thyroid Diseases.
10.3803/EnM.2016.31.3.379
- Author:
Won Sang YOO
1
;
Hyun Kyung CHUNG
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea. chkendo@dankook.ac.kr
- Publication Type:Review
- Keywords:
Autoimmune thyroid disease;
Graves disease;
Hashimoto disease
- MeSH:
Causality;
Consensus;
Drug Therapy;
Genes, rel;
Graves Disease;
Hashimoto Disease;
Hyperthyroidism;
Hypothyroidism;
Risk Assessment;
Thyroid Diseases*;
Thyroid Gland*;
Thyroiditis, Autoimmune;
Thyroxine
- From:Endocrinology and Metabolism
2016;31(3):379-385
- CountryRepublic of Korea
- Language:English
-
Abstract:
Autoimmune thyroid disease (AITD) includes hyperthyroid Graves disease, hypothyroid autoimmune thyroiditis, and subtle subclinical thyroid dysfunctions. AITD is caused by interactions between genetic and environmental predisposing factors and results in autoimmune deterioration. Data on polymorphisms in the AITD susceptibility genes, related environmental factors, and dysregulation of autoimmune processes have accumulated over time. Over the last decade, there has been progress in the clinical field of AITD with respect to the available diagnostic and therapeutic methods as well as clinical consensus. The updated clinical guidelines allow practitioners to identify the most reasonable and current approaches for proper management. In this review, we focus on recent advances in understanding the genetic and environmental pathogenic mechanisms underlying AITD and introduce the updated set of clinical guidelines for AITD management. We also discuss other aspects of the disease such as management of subclinical thyroid dysfunction, use of levothyroxine plus levotriiodothyronine in the treatment of autoimmune hypothyroidism, risk assessment of long-standing antithyroid drug therapy in recurrent Graves' hyperthyroidism, and future research needs.
